Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Friche

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Biochemical Pharmacology|June 17, 2000
Characterisation of non-P-glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantroneD Nielsen, J Eriksen, C Maare, et al.
British Journal of Cancer|December 1, 1989
Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulatorsM Sehested, P B Jensen, T Skovsgaard, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluationP B Jensen, H Roed, T Skovsgaard, et al.
Biochemical Pharmacology|May 25, 1993
Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistanceP B Jensen, B S Sørensen, M Sehested, et al.
Cytotechnology|January 1, 1993
Altered DNA topoisomerase II in multidrug resistanceW T Beck, M K Danks, J S Wolverton, et al.
Cancer Research|October 1, 1991
Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase IIP B Jensen, P S Jensen, E J Demant, et al.
Cancer Research|March 15, 1993
Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cellsM K Danks, M R Warmoth, E Friche, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Biochemical Pharmacology|June 17, 2000
Characterisation of non-P-glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantroneD Nielsen, J Eriksen, C Maare, et al.
British Journal of Cancer|December 1, 1989
Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulatorsM Sehested, P B Jensen, T Skovsgaard, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluationP B Jensen, H Roed, T Skovsgaard, et al.
Biochemical Pharmacology|May 25, 1993
Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistanceP B Jensen, B S Sørensen, M Sehested, et al.
Cytotechnology|January 1, 1993
Altered DNA topoisomerase II in multidrug resistanceW T Beck, M K Danks, J S Wolverton, et al.
Cancer Research|October 1, 1991
Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase IIP B Jensen, P S Jensen, E J Demant, et al.
Cancer Research|March 15, 1993
Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cellsM K Danks, M R Warmoth, E Friche, et al.
Pageof 3